Plaintiffs claimed the two companies “conspired to delay the introduction of generic ezetimibe to the market, in violation of Sections 1 and 2 of the Sherman Act.”
'Unexplained Large Reverse Payment': Zetia Antitrust Claims Scheduled for Jury Trial in April
Leave a Reply